Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ESO-T01 delivers its first four multiple myeloma case reports.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
PD-(L)1 x VEGF bispecifics prove a big draw.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.